Lung Cancer in Non-smokers in Czech Republic: Data from LUCAS Lung Cancer Clinical Registry.
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ genetics
Carcinoma, Non-Small-Cell Lung
/ diagnosis
Czech Republic
/ epidemiology
Ex-Smokers
Female
Humans
Lung Neoplasms
/ diagnosis
Male
Middle Aged
Mutation
Neoplasm Staging
Non-Smokers
Pneumonectomy
Prospective Studies
Registries
Small Cell Lung Carcinoma
/ diagnosis
Smokers
Time Factors
Treatment Outcome
Young Adult
Lung cancer
NSCLC
clinical registry
driving mutations
non-smokers
survival
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
30
08
2021
revised:
15
10
2021
accepted:
18
10
2021
entrez:
4
11
2021
pubmed:
5
11
2021
medline:
16
11
2021
Statut:
ppublish
Résumé
LUCAS is a clinical lung cancer registry (ClinicalTrials.gov identifier is NCT04228237), prospectively collecting data from newly diagnosed lung cancer patients in seven pneumooncology centers in the Czech Republic, since June 1, 2018. The aim of the study was to assess the stage of the disease at the time of diagnosis, percentage of morphological types, survival, percentage of driving mutations, eligibility for radical surgery, and percentage of patients who undergo radical surgery, in the non-smoking population in comparison with smokers and former smokers. The total number of patients in the registry at the time of the analysis was 2,743. Only 2,439 patients with complete records (smoking status, stage, and type of tumor) were included in this study. The analysis indicated that non-smokers are diagnosed at a later stage of the disease but they have a better survival rate than smokers. Fewer smokers with stage III disease who are eligible for radical surgery will undergo surgery compared to non-smokers with the same clinical stage. Driving mutations are more common in non-smokers, even after adjustment for the more frequent occurrence of adenocarcinoma in the group of non-smokers. The data from LUCAS registry are consistent with already known facts, suggesting that the LUCAS registry is a useful clinical tool.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
LUCAS is a clinical lung cancer registry (ClinicalTrials.gov identifier is NCT04228237), prospectively collecting data from newly diagnosed lung cancer patients in seven pneumooncology centers in the Czech Republic, since June 1, 2018. The aim of the study was to assess the stage of the disease at the time of diagnosis, percentage of morphological types, survival, percentage of driving mutations, eligibility for radical surgery, and percentage of patients who undergo radical surgery, in the non-smoking population in comparison with smokers and former smokers.
PATIENTS AND METHODS
METHODS
The total number of patients in the registry at the time of the analysis was 2,743. Only 2,439 patients with complete records (smoking status, stage, and type of tumor) were included in this study.
RESULTS
RESULTS
The analysis indicated that non-smokers are diagnosed at a later stage of the disease but they have a better survival rate than smokers. Fewer smokers with stage III disease who are eligible for radical surgery will undergo surgery compared to non-smokers with the same clinical stage. Driving mutations are more common in non-smokers, even after adjustment for the more frequent occurrence of adenocarcinoma in the group of non-smokers.
CONCLUSION
CONCLUSIONS
The data from LUCAS registry are consistent with already known facts, suggesting that the LUCAS registry is a useful clinical tool.
Identifiants
pubmed: 34732425
pii: 41/11/5549
doi: 10.21873/anticanres.15368
doi:
Substances chimiques
Biomarkers, Tumor
0
Banques de données
ClinicalTrials.gov
['NCT04228237']
Types de publication
Comparative Study
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
5549-5556Informations de copyright
Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.